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The purpose of this study was to design a submicron-sized liposomal non-steroidal anti-
inflammatory drug (NSAID) preparation that targets the retina via topical instillation of eye
drops. Bromfenac (BRF)-loaded liposomes were prepared using the calcium acetate
gradient method. Liposome sizes and encapsulation efficiencies were optimized by
screening several liposome formulations of lipid, drug concentration, and buffer solution.
BRF entrapment efficiency was greater than 90% using this method, and was low using
conventional hydration methods. High initial BRF loading using the pH gradient method
caused aggregation of liposomes. To circumvent aggregation, the negatively charged lipid
dicetylphosphate was incorporated into liposomes, which formed anion layer preventing
coalescence. Release of BRF from liposomes was sustained for several hours depending on
lipid concentration, inner water phase, initial drug amounts, and surface properties. Sur-
face modification with chitosan (CS), a mucoadhesive cationic polymer, was achieved
using electrostatic interactions of negatively charged liposomes. The optimal concentra-
tion of CS for evasion of liposome aggregation was 0.15%.
ª 2013 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction have the potential to be safe and effective alternatives toNon-steroidal anti-inflammatory drugs (NSAIDs) are widely
used to treat severe inflammations and related diseases of the
ocular posterior segment, such as retinal and choroidal neo-




ang Pharmaceutical Univcorticosteroids in topical treatments of ocular inflammation.
Intravitreal injections are commonly used to deliver these
drugs to the back of the eye, though multiple injections can
induce complications such as cataracts, vitreous hemor-
rhages, and retinal detachment [4e6]. Topical applicationwithsity
ersity. Production and hosting by Elsevier B.V. All rights reserved.
a s i a n j o u rn a l o f p h a rm a c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 1 0 4e1 0 9 105eye drops is safe and easy to use. However, corneal and
conjunctival epithelia, along with tear film, serve as biological
barriers that protect the eye from potentially harmful sub-
stances and drugs. Therefore, conventional eye drops do not
allow the retention of sufficient drug in the posterior area.
Several colloidal drug delivery systems have enhanced
ocular bioavailability of eye drop-administered drugs [7,8].
In our previous study, we revealed that submicron-sized
(100 nm) liposomes are potential drug carriers eye drop
preparations for targeting the retina [9]. Previously, we iden-
tified physico-chemical properties of liposomes, such as par-
ticle size, surface properties, and composition, significantly
influence the fates of the drug and carrier [10]. In particular,
surface modification using cationic mucoadhesive polymers
such as chitosan (CS) may improve delivery efficiency to the
retina [11]. Furthermore, we have reported that topical lipo-
somal treatments achieved retinal delivery of NSAID by pro-
moting non-corneal drug penetration [12].
In the present study, several liposomal formulations were
prepared for NSAID delivery. Sodium bromfenac (BRF) was
used as a model NSAID drug and was encapsulated in lipo-
somes using the calcium acetate gradient method. We eval-
uated the effects of lipid composition and CS-modified surface
properties on in vitro release profiles.2. Materials and method
2.1. Materials
L-a-Distearoylphosphatidylcholine (DSPC) was purchased
from Nippon Oil and Fats Co., Ltd. (Tokyo, Japan). BRF was
provided by the Wakamoto Pharmaceutical Co., Ltd. (Tokyo,
Japan). Cholesterol and Dicetylphosphate (DCP) were obtained
from SigmaeAldrich (St. Louis, MO, USA). CS of around
1000 Da [13] was supplied by Katakura Chikkarin Co., Ltd.
(Tokyo, Japan). 2-Morpholinoethanesulfonic acid mono-
hydrate (MES) was purchased from Nacalai Tesque (Kyoto,
Japan). Hank’s balanced salt solution (HBSS) was purchased
from GIBCO BRL (Grand Island, NY, USA). All other chemicals
were commercial products of reagent grade.
2.2. Preparation of liposomes using the acetate salt pH
gradient method
DSPC, DCP, and cholesterol (lipid concentrations: 20.4 or
40.8 mM) were dissolved in a small amount of chloroform in a
round-bottom flask and were dried in a rotary evaporator
under reduced pressure at 40 C to form a thin lipid film. The
filmwas dried in a vacuum oven overnight to ensure complete
removal of the solvent. Subsequently, the lipid film was hy-
drated at 70 C with acetate salt solutions (120-mM calcium
acetate or 150-mM sodium acetate) by vortexing. The resulting
multilamellar vesicles were frozen and thawed 4 times using a
freezer and awater bathmaintained at 40 C. Submicron-sized
liposomes were prepared using an extruder (LipoFast-Pneu-
matic; Avestin, Inc., Ottawa, Canada) with a size-controlled
polycarbonate membrane (0.1-mm membrane filter pore size).
Extrusion was performed 41 times under nitrogen pressure
(200 psi). To create an acetate salt concentration gradientacross the liposomalmembrane, theacetate salt of theexternal
liposomemediumwas replacedwithHBSSeMESbuffer (pH6.0)
at 4 C in two dialysis steps. BRF powder was mixed with lipo-
somes to final concentrations of 1e5 mg/ml. Remote loading
was achieved by incubation of the liposomes at 37 C.
Surface modification of negatively charged liposomes by
positively charged CS was mediated by electrostatic in-
teractions. CS polymers were dissolved in HBSSeMES buffer.
Surface modification of prepared liposomes was accom-
plished by mixing aliquots of the liposomal suspension with
equal volumes of CS solution.
2.3. Characterization of liposomes
Particle size of liposomes was measured in aliquots of lipo-
somal suspension diluted in large volumes of distilled water
using the dynamic light scatteringmethod (Zetasizer Nano ZS,
Malvern, Worcestershire, UK). Liposome zeta potentials were
measured using the laser Dopplermethod (Zetasizer Nano ZS).
To determine the efficiency of liposomal BRF, BRF-loaded li-
posomes were separated from free BRF using ultracentrifu-
gation (231,000 g, 45 min) at 4 C. BRF concentrations in the
supernatants were determined by HPLC using a COSMOSIL
5C18-MS-II column (Nacalai Tesque, Tokyo, Japan) with a mo-
bile phase containing Milli-Q/methanol ¼ 3/7 and 0.04% acetic
acid at 275 nm. Entrapment efficiency of liposomes was
calculated using the following equation: % entrapment
efficiency¼ (AtotalAfree)/Atotal 100,where Atotal was the
total drug amount in liposomes when methanol was added,
and Afree was the amount of free drug in liposome solutions.
BRF-loaded liposomes were observed using transmission
electron microscopy (TEM). The samples were absorbed to a
400 mesh carbon-coated grid and were put on 2% phospho-
tungstic acid solution (pH 7.4) for a few seconds for negative
staining. The liposomes were observed by a TEM (JEM-1200EX;
JEOL, Tokyo, Japan) at an acceleration voltage of 80 kV. Digital
images were taken with a Veleta TEM CCD camera (Olympus
Soft Imaging System, Munster, Germany).
2.4. Release test
The BRF release study was conducted in phosphate buffered
saline (PBS) at pH 7.4, which simulated tear fluid. BRF-loaded
liposomes (0.5 ml) were transferred into dialysis bags. The
bags were then soaked in PBS at 37 C (49.5 ml). At a pre-
determined time, 0.2 ml of receptor phase was removed and
replaced with an equal volume of fresh PBS. Released BRF was
quantified using HPLC.3. Results and discussion
3.1. Preparation of BRF-loaded liposomes using the
calcium acetate gradient method
Rigid liposomes generally exhibit higher stability and are
capable of maintaining entrapped substances. Our previous
study confirmed that DSPC-liposomes with higher phase
transition temperatures are more effective than egg phos-
phatidylcholine (EPC) at delivering drugs to the retina [9].


















DSPC/Chol ¼ 8/1 20.4 Calcium acetate 1.0 137.9 0.120 3.5 96.0  0.90
DSPC/Chol ¼ 8/1 20.4 Calcium acetate 2.0 249.0 0.530 3.3 96.9  0.11
DSPC/Chol ¼ 8/1 20.4 Calcium acetate 3.0 428.6 0.514 5.0 93.2  0.18
DSPC/DCP/Chol ¼ 8/0.5/1 20.4 Calcium acetate 1.0 120.6 0.060 27.0 97.4  1.98
DSPC/DCP/Chol ¼ 8/0.5/1 20.4 Calcium acetate 2.0 135.5 0.153 24.0 98.5  0.54
DSPC/DCP/Chol ¼ 8/0.5/1 20.4 Calcium acetate 3.0 153.2 0.164 21.7 96.3  0.05
DSPC/DCP/Chol ¼ 8/0.2/1 20.4 Calcium acetate 2.0 150.3 0.140 20.3 98.3  0.02
DSPC/DCP/Chol ¼ 8/2/1 20.4 Calcium acetate 2.0 173.0 0.326 33.7 74.5  0.23
DSPC/DCP/Chol ¼ 8/0.5/1 20.4 Sodium acetate 1.0 116.9 0.056 48.5 86.7  1.10
DSPC/DCP/Chol ¼ 8/0.5/1 40.8 Calcium acetate 1.0 123.8 0.075 35.1 99.1  0.14
DSPC/DCP/Chol ¼ 8/0.5/1 40.8 Calcium acetate 2.5 149.2 0.345 34.9 99.2  0.00
DSPC/DCP/Chol ¼ 8/0.5/1 40.8 Calcium acetate 5.0 123.8 0.109 22.5 95.9  0.26
Fig. 1 e Representative TEM image of BRF-loaded
liposomes. Lipid composition of liposome, DSPC/DCP/
Chol [ 8/0.5/1; Lipid concentration, 20.4 mM; Inner
water phase, Calcium acetate; Initial drug concentration,
1.0 mg/ml. The scale bar is 100 nm.
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liposomes.
In this preliminary study, various loading methods were
compared to optimize entrapment efficiency. The entrapment
efficiency of liposomes containing DSPC/Chol ¼ 8/1 was
greater than 90% using the calcium acetate gradient method
for each of the formulations in Table 1, whereas the conven-
tional hydration method achieved only 20.4% entrapment.
The calcium acetate gradient method exploits large differ-
ences in permeability coefficients across liposome bilayers of
cation andacetic acidmolecules. Aplausiblemechanismof drug
uptake in response to transmembrane calcium acetate gradi-
ents has been described [14].When transmembrane gradients of
calcium acetate are created, membrane impermeable calcium
ions remain trapped in the liposome internal phase, while
membrane-permeable protonated acetic acid molecules leak
out and behave as proton shuttles. The leakage of protonated
acetic acid from liposomes increases the pH in liposomes, and
the resulting pH gradient serves as an efficient driving force to
loadweak acids inside lipid vesicles.Weakly acidicmolecules in
their neutral protonated forms diffuse into the slightly alkaline
liposome internal phase. Under these conditions, BRF loses its
proton, becomes charged, and loses membrane-permeability.
Particle size is an important factor in the efficiency of drug
delivery via liposomes. After topical instillation of eye drops,
the delivery of coumarin-6 was extensively improved by
reducing liposomal particle size to less than a micron [10].
Therefore, it was preferable to limit liposome particle size to
100 nm after loading drugs. In this study, almost all liposome
preparations after drug loading were narrowly distributed
around 100 nm by extrusion.
TEM was used to observe BRF-loaded liposomes as shown
in Fig. 1. Encapsulated and precipitated BRF forms aggregates
that appear as linear structures and induce a change in lipo-
somal shape that results in a characteristic “coffee bean”
appearance [15].
3.2. Effects of liposomal formulation parameters during
the drug loading process on liposomal properties
Loading conditions that correspond with high remote loading
of drugs were optimized, particularly initial drug amount. As
shown in Table 1, initial BRF concentrations affected particlesize and entrapment efficiency. Three different initial con-
centrations (1, 2, and 3 mg/ml) were tested for efficiency of
drug loading into liposomes (DSPC/Chol ¼ 8/1). High entrap-
ment efficiency of over 90% was achieved for each initial drug
concentration. The entrapment efficiency of BRF was main-
tained with increased initial BRF concentrations. However,
liposomal aggregation increased with initial drug concentra-
tion (3 mg/ml), resulting in a larger particle size (428.6 nm).
With high drug concentrations, encapsulated drug near the
liposomal surface may interact with counter ions in the outer
phase and induce aggregation.
To circumvent this aggregation problem, lipid membranes
of DCP-bearing negatively charged liposomes (DSPC/DCP/
Chol ¼ 8/0.5/1) were prepared to encapsulate BRF by remote
loading. Liposomal aggregation was avoided after drug
loading with high concentrations of BRF. The polar group
of DCP was negative in water, and a counter-ion was released
resulting in negative zeta potential. Consequently, the inter-
face was charged and anion layer was consequently










































Fig. 2 e Cumulative release (% of amount loaded) of BRF from liposomes in PBS at 37 C. (A) Effect of final lipid concentrations
of 20.4 and 40.8 mM. (B) Effect of the inner water phase salts calcium and sodium acetate. Data are expressed as the
mean ± SD of three samples.
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1, 8/0.2/1, 8/0.5/1, and 8/2/1) were prepared to optimize DCP
concentration in the liposome. DCP maintained submicron
sizes after drug loading, although high DCP concentrations
(DSPC/DCP/Chol ¼ 8/2/1) decreased entrapment efficiency to
74.5% reflecting decreased lipid membrane fluidity and
inhibited drug permeability. The formulation containing
DSPC/DCP/Chol ¼ 8/0.5/1 was used in the following experi-
ments as an optimal lipid formulation.
3.3. Effects of lipid concentration and inner water phase
on BRF release from liposomes
Release profiles of BRF from liposomes were investigated in
PBS at 37 C using the dialysis method (Fig. 2). Formulations
prepared by the calcium acetate gradient method exhibited a






















Fig. 3 e Effect of initial BRF loading amount on BRF release profi
enlarged part from 0 to 6 h (B). Data are expressed as the meansuggesting that BRF was predominantly entrapped inside the
liposome. The driving force behind sustained drug release
from liposomes is the drug concentration gradient across the
liposome membrane. BRF release rates decreased with higher
lipid concentration (40.8 mM vs. 20.4 mM; Fig. 2A). Liposomal
particles also increased with high lipid concentrations.
Therefore, drug concentration gradients across liposome
membranes were lowered because of reduced BRF loads of
liposomal particles containing lipid at 40.8 mM, compared
with 20.4 mM.
The effects of sodium acetate and calcium acetate in the
inner water phase on BRF release were examined (Fig. 2B).
When sodium acetic acid was used as the inner phase of li-
posomes, the lag-time before BRF release was not observed,
whereas lag-time occurred in calcium acetate. Changed




















les in PBS at 37 C (A). The figure on the right shows the




















Fig. 4 e Effect of liposomal surface modification with 0.15%
CS on BRF release profiles in PBS at 37 C. Data are
presented as the mean ± SD of three samples.
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loading process on liposomal BRF release
We examined whether initial BRF concentrations affected
drug release kinetics (Fig. 3A). BRF release kinetics showed
marked leakage upon loading with high drug concentrations
(5 mg/ml), whereas there was a considerable drug release lag-
time with 1- and 2.5-mg/ml BRF (Fig. 3B). This may be
explained by initial bursts of encapsulated drug release from
near the lipid bilayer. However, there is no satisfactory rep-
resentation of the experimental kinetics and of the observed
lag-time. BRF loading is driven by protonation and subsequent
deprotonation of BRF within liposome. Precipitation of BRF in
the hydrophilic interior of the vesicle when BRF solubility
exceeded is shown in the TEM image (Fig. 1). Dissolution rates
of some BRF precipitates in liposomes may be delayed in
studies of the initial release stage, which causes lag-time drug
release. These results indicate that this time lag may be sen-
sitive to changes in BRF concentrations.
3.5. CS surface modification of BRF-loaded liposomes
Modification of liposome surfaces was performed by mixing
liposomes with polymer solutions containing various CS con-
centrations. Particle sizes and zeta potentials of the resulting
liposomes are shown in Table 2. The zeta potential of unmod-
ified liposomes was negative owing to negatively charged
DCP. The zeta potential of CS-modified liposomes shifted to
neutral with increasing CS concentration. Although the zeta
potential of these liposomes increased with CS concentrations,
particle size, polydispersity, and aggregation of liposomes also
increased. Amino groups of CS chains interact stronglywith the
phosphate groups of DCP through combined hydrogen and
electrostatic forces, leading to adhesion of liposomes and for-
mation of aggregates. Therefore, we used a 0.15% CS solution,
which did not induce aggregation and exhibited small particle
size, low polydispersity index, and high zeta potential. In our
previous study, the mucoadhesive property of CS solution was
evaluated by the interaction between mucin particles and CS
[16]. Based on these data, 0.15% CS was expected to provide
mucoadhesiveness to the liposomes because >0.05% CS could
be interacted by themucin particles. This was considered to be
the ideal concentration for surface modification to deliver the
drug to the posterior segment of the eye.
Release rates of either unmodified or CS-modified lipo-
somes were lower than that of the BRF solution (Fig. 4). BRFTable 2 e Effect of surface modification with CS on the








Unmodified 108.7 0.049 32.5
0.05 108.7 0.057 25.7
0.10 111.2 0.107 19.0
0.15 112.3 0.053 17.6
0.20 138.4 0.210 14.6
0.40 3882.0 0.244 9.5release was significantly prolonged by liposome encapsula-
tion, and further by CS modification. Importantly, modifica-
tion of liposomes with CS did not alter drug release profiles.
However, polymer modification of liposomes reduced the
initial rate of drug release. In general, drug release depends on
membrane permeability, which is affected by fluidity of the
lipid bilayer. Drug permeation rates were reduced in the
presence of CS on the liposomal surface. This may reflect a
close association between CSmolecules and liposome surface
that cause formation of denser shells, which probably restrict
bilayer fluidity and permeability [17,18].4. Conclusion
Our previous study demonstrated that 100-nm DSPC-
liposomes can delivere drugs to the posterior region after
topical administration. The purpose of the present study was
to prepare appropriate liposomal formulations for ophthalmic
delivery (high BRF loading and 100-nm liposome). The model
NSAID BRF was encapsulated into liposomes using the pH
gradient method. Formulations were optimized to achieve
almost 100% drug loading efficiency. BRF release from lipo-
somes depended on the lipid, inner water phase, and the
initial drug amount. Further investigations are required to
evaluate the delivery efficiency of these formulations in vivo,
and to further optimize liposomal formulations that can
deliver drugs to the posterior segment of the eye.
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